Noncoding RNA in drug resistant sarcoma

Xiaoyang Li, Jacson K. Shen, Francis J. Hornicek, Tao Xiao _ and Zhenfeng Duan

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:69086-69104. https://doi.org/10.18632/oncotarget.19029

Metrics: PDF 1568 views  |   HTML 4147 views  |   ?  


Xiaoyang Li1,2, Jacson K. Shen2, Francis J. Hornicek2, Tao Xiao1 and Zhenfeng Duan2

1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China

2Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 02114, USA

Correspondence to:

Tao Xiao, email: [email protected]

Zhenfeng Duan, email: [email protected]

Keywords: noncoding RNA (ncRNA), microRNA (miR), long noncoding RNA (lncRNA), drug resistance, sarcoma

Received: May 04, 2017     Accepted: June 26, 2017     Published: July 06, 2017


Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant development of multidisciplinary treatments for sarcoma, survival rates have reached a plateau. Chemotherapy has been extensively used for sarcoma treatment; however, the development of drug resistance is a major obstacle limiting the success of many anticancer agents. Sarcoma biology has traditionally focused on genomic and epigenomic deregulation of protein-coding genes to identify the therapeutic potential for reversing drug resistance. New and more creative approaches have found the involvement of noncoding RNAs, including microRNAs and long noncoding RNAs in drug resistant sarcoma. In this review, we discuss the current knowledge of noncoding RNAs characteristics and the regulated genes involved in drug resistant sarcoma, and focus on their therapeutic potential in the future.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19029